Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dapagliflozin’s CKD performance sends heart failure messages

Key clinical point: Patients with chronic kidney disease treated with dapagliflozin had a significant reduction in hospitalizations for heart failure.

Major finding: Dapagliflozin treatment linked with a significant 49% reduction in all hospitalizations for heart failure relative to control patients.

Study details: DAPA-CKD, a multicenter, randomized trial with 4,304 patients with chronic kidney disease.

Disclosures: DAPA-CKD was funded by AstraZeneca, the company that markets dapagliflozin (Farxiga). Dr. McMurray’s employer, Glasgow University, has received payments from AstraZeneca and several other companies to compensate for his time overseeing various clinical trials.


McMurray JJV. HFSA 2020.